1018909-82-4

Basic information

• Product Name: (3R,4R)-tert-butyl 3-{{6-[benzyl(tert-butoxycarbonyl)amino]-4-methylpyridin-2-yl}methyl}-4-{(1S,4R)-4,7,7-trimethyl-3-oxo-oxabicyclo[2.2.1]heptane-1-carbonyloxy}pyrrolidine-1-carboxylate
• Synonyms: (3R,4R)-tert-butyl 3-{{6-[benzyl(tert-butoxycarbonyl)amino]-4-methylpyridin-2-yl}methyl}-4-{(1S,4R)-4,7,7-trimethyl-3-oxo-oxabicyclo[2.2.1]heptane-1-carbonyloxy}pyrrolidine-1-carboxylate
• CAS NO: 1018909-82-4
• Molecular Weight: 677.838
• Mol File: 1018909-82-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (3R,4R)-tert-butyl 3-{{6-[benzyl(tert-butoxycarbonyl)amino]-4-methylpyridin-2-yl}methyl}-4-{(1S,4R)-4,7,7-trimethyl-3-oxo-oxabicyclo[2.2.1]heptane-1-carbonyloxy}pyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (3R,4R)-tert-butyl 3-{{6-[benzyl(tert-butoxycarbonyl)amino]-4-methylpyridin-2-yl}methyl}-4-{(1S,4R)-4,7,7-trimethyl-3-oxo-oxabicyclo[2.2.1]heptane-1-carbonyloxy}pyrrolidine-1-carboxylate(1018909-82-4)
• EPA Substance Registry System: (3R,4R)-tert-butyl 3-{{6-[benzyl(tert-butoxycarbonyl)amino]-4-methylpyridin-2-yl}methyl}-4-{(1S,4R)-4,7,7-trimethyl-3-oxo-oxabicyclo[2.2.1]heptane-1-carbonyloxy}pyrrolidine-1-carboxylate(1018909-82-4)

Safety Data

• Hazardous Substances Data: 1018909-82-4(Hazardous Substances Data)

Upstream product

• 39637-74-6 (1S)-(-)-camphanic chloride 
• 67111-66-4 (-)-camphanic acid 
• 100-39-0 benzyl bromide 
• 848472-36-6 tert-butyl (4,6-dimethylpyridin-2-yl)carbamate 
• 114214-49-2 1-tert-butoxycarbonyl-3,4-epoxypyrrolidine 
• 5407-87-4 2-Amino-4,6-dimethylpyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 

Downstream Products

• 1018909-84-6 (3'R,4'R)-tert-butyl 3'-{{6''-[benzyl(tert-butoxycarbonyl)-amino]-4''-methylpyridin-2''-yl}methyl}-4'-hydroxypyrrolidine-1'carboxylate 

Relevant articles and documents

SPECIFIC NNOS INHIBITORS FOR THE THERAPY AND PREVENTION OF HUMAN MELANOMA

Methods for melanoma treatment and prevention with selective nitric oxide synthase inhibitor compounds and related pharmaceutical compositions, alone or in conjunction with one or more other melanoma therapies.

Unexpected binding modes of nitric oxide synthase inhibitors effective in the prevention of a cerebral palsy phenotype in an animal model

Selective inhibition of the neuronal isoform of nitric oxide synthase NOS (nNOS) has been shown to prevent brain injury and is important for the treatment of various neurodegenerative disorders. However, given the high active site conservation among all three NOS isoforms, the design of selective inhibitors is an extremely challenging problem. Here we present the structural basis for why novel and potent nNOS inhibitors exhibit the highest level of selectivity over eNOS reported so far (～3,800-fold). By using a combination of crystallography, computational methods, and site-directed mutagenesis, we found that inhibitor chirality and an unanticipated structural change of the target enzyme control both the orientation and selectivity of these novel nNOS inhibitors. A new hot spot generated as a result of enzyme elasticity provides important information for the future fragment-based design of selective NOS inhibitors.